Advertisement

Advertisement
Nicholas D. James, PhD, MBBS, on the STAMPEDE Trial: Long-Term Subgroup Analysis by Metastatic Burden in Hormone-Naive Prostate Cancer

Nicholas D. James, PhD, MBBS, on the STAMPEDE Trial: Long-Term Subgroup Analysis by Metastatic Burden in Hormone-Naive Prostate Cancer

DNA Vaccine for Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

In a phase II study reported in the Journal of Clinical Oncology, McNeel et al found that a DNA vaccine encoding prostatic acid phosphatase did not improve 2-year metastasis-free survival vs control treatment in patients with progressive, nonmetastatic, castration-sensitive prostate cancer. Potential benefit was observed in a subgroup of patients with rapidly progressive disease.

Long-Term Follow-up of Salvage Short-Term ADT Plus Radiotherapy After Radical Prostatectomy

As reported in The Lancet Oncology by Carrie et al, the 112-month follow-up of the French phase III GETUG-AFU 16 trial has confirmed the initial 5-year report of the trial, which reported improved progression-free survival with the addition of short-term androgen-deprivation therapy (ADT) to radiotherapy as salvage treatment in men with rising prostate-specific antigen after radical prostatectomy for prostate cancer.

Mindfulness Training for Men Diagnosed With Prostate Cancer Who Are on Active Surveillance

Mindfulness Training for Men Diagnosed With Prostate Cancer Who Are on Active Surveillance

Accumulating evidence supports the value of mindfulness meditation for improving psychological, physiologic, and emotional well-being in patients with cancer...

Targeted Therapy Moves Into Metastatic Castration-Resistant Prostate Cancer With Strong Showing by Olaparib and Rucaparib

Targeted Therapy Moves Into Metastatic Castration-Resistant Prostate Cancer With Strong Showing by Olaparib and Rucaparib

Treatment with olaparib delayed disease progression, and early survival data suggest a positive trend in favor of olaparib compared with newer hormonal agents...

Apalutamide Treatment for Metastatic Castration-Sensitive Prostate Cancer and Health-Related Quality of Life

Apalutamide Treatment for Metastatic Castration-Sensitive Prostate Cancer and Health-Related Quality of Life

In an analysis of the phase III TITAN trial reported in The Lancet Oncology, Agarwal et al found that treatment with apalatuamide was associated with preserved health-related quality of life, including pain and fatigue outcomes, in patients with metastatic castration-sensitive prostate cancer receiving androgen-deprivation therapy.

Advertisement


Advertisement